Skip to main content
Premium Trial:

Request an Annual Quote

Nastech Wins Phase I SBIR Grant to Develop siRNA-Based Flu Drugs

NEW YORK (GenomeWeb News) – Nastech Pharmaceutical has obtained a Phase I Small Business Innovation Research grant from the National Institutes of Health to help it develop small-interfering RNA influenza drugs.
The company did not disclose the mount of the grant but Phase I SBIRs typically do not exceed $100,000.
Nastech is developing siRNA therapeutics that specifically target conserved regions of the influenza viral genome. The company obtained the methods to do this when it acquired Galenea in February 2006.
The grant will help Nastech to design and optimize siRNAs against seasonal and avian influenza viruses, test in vivo activity of new siRNA delivery agents, and evaluate viral drug resistance mechanisms, Nastech said in a statement.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.